NexgenRx Inc. TSX VENTURE: NXG

TORONTO, ONTARIO--(Marketwire - Sept. 24, 2008) - NEXGENRX INC. ("NexgenRx" or the "Company") (TSX VENTURE:NXG) is pleased to announce the closing of a private placement subscription for an aggregate of 3,500,000 common shares at a price of $0.20 per share for gross proceeds of $700,000. The offering was completed on a non-brokered basis and no finders' fees were paid. The sole subscriber under this offering was Co-operators Life Insurance Company, which is a key investor and strategic partner of the Corporation. In accordance with applicable securities laws, the foregoing common shares are subject to a four-month hold period that will expire on January 24, 2009.

"We are delighted with The Co-operator's decision to invest additional capital into our Company as we position NexgenRx for continued growth in the next phase of our evolution" stated Ron Loucks, NexgenRx' President and CEO.

"Our decision to invest in NexgenRx is based on our commitment to growing our business with a dynamic organization that continues to develop and enhance administration and claims adjudication solutions for the Canadian market," replied Kevin Daniel, Chief Operating Officer of Co-operators Life Insurance Company.

About Co-operators Life Insurance Company

Co-operators Life Insurance Company is a wholly owned subsidiary of The Co-operators Group Ltd., the leading Canadian-owned multi-product insurance company. Co-operators Life provides group life, disability, extended health and dental benefits to over 300,000 plan members across Canada, and has been an underwriter of group insurance plans for more than fifty years.

About NexgenRx

NexgenRx provides leading-edge fully integrated health benefits solutions. Utilizing state-of-the-art technology, the Company offers administration and adjudication services related to group health benefit plans offered by various organizations for the benefit of their plan members. More information on NexgenRx can be found at www.nexgenrx.com.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.